查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813964

心房顫動市場規模、佔有率和趨勢分析報告：按治療類型、最終用途、地區和細分市場預測，2025 年至 2033 年

Atrial Fibrillation Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological Treatment, Non-pharmacological Treatment), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

心房顫動市場摘要

2024 年全球心房顫動市場價值估計為 268.9 億美元，預計到 2033 年將達到 653.3 億美元，2025 年至 2033 年的複合年成長率為 10.44%。

心房顫動市場的發展受到疾病負擔不斷增加、治療和診斷技術的快速進步以及向遠端患者監護轉變的推動。

隨著臨床實踐逐漸轉向更有效率、以患者為中心的模式，能夠將這些進步融入綜合護理解決方案的公司有望主導市場成長。旨在擴大創新療法可及性的策略聯盟和收購可能會進一步加劇市場競爭。

由於人口老化以及高血壓、糖尿病和肥胖等風險因素的增加，心房顫動的盛行率不斷上升，這是推動市場成長的主要因素。心房顫動是中風和心臟衰竭的主要原因之一，醫療保健系統優先考慮早期診斷和有效管理。患者數量的增加直接增加了對藥物治療和先進介入手術的需求。 2024 年 5 月，CDC 將心房顫動 (AFib) 列為美國最常見的心律不整疾病。到 2030 年，患有心房顫動的美國人預計將增加到 1,210 萬人。心房顫動每年導致約 158,000 人死亡，約七分之一的中風病例是由心房顫動引起的。

心導管電氣燒灼術、3D 電解剖映射和穿戴式心電圖 (ECG) 監測器等技術進步正在提高心房顫動治療的準確性和安全性。人工智慧在心律不整檢測和程序規劃中的整合，使得診斷更快、更準確以及標靶治療成為可能。這些技術進步正在將治療選擇擴展到更多患者、改善療效並降低復發率。據心律學會 (HRS) 稱，2025 年 4 月在心律 2025 大會上發表的一項新研究展示了人工智慧 (AI) 如何提高心房顫動 (AFib) 治療的安全性和成功率。由人工智慧驅動的 DeePRISM 模型能夠在消融過程中進行即時波形分析，從而改善持續性心房顫動患者的預後。專家強調了人工智慧透過提高臨床可靠性和程序準確性來改變電生理學的潛力。

遠端監控和遠端醫療平台的採用正在改變心房顫動的管理方式，使臨床環境之外的持續心律監測成為可能。穿戴式心電圖設備和智慧型手機連結應用程式為患者和醫生提供即時數據，支援主動管理和早期療育。醫療保健提供者正在利用這些工具有效地監測更大的患者群體，特別是在術後追蹤和長期照護方面。 2025 年 5 月，墨爾本腦中心的研究人員開發了一個人工智慧模型，能夠透過分析腦部 MRI 掃描來檢測中風患者中的無症狀性心房顫動 (AF)。該技術在區分 AF 相關中風方面表現出很高的準確性（AUC 0.81），提供了一種非侵入性且有效的檢測方法。這種方法可以透過標記需要進一步心臟評估的隱藏 AF 病例來加速診斷並個性化中風治療。

叢集柱狀圖顯示了1990年至2021年美洲地區與心房顫動相關的傷殘調整生命年（DALY）和死亡率的成長情況。 DALY從每10萬人117.14人增加到120.68人，死亡率從每10萬人4.18人增加到4.84人。這反映出醫療保健系統持續承受日益成長的壓力，尤其是在早期發現和獲得先進治療機會仍然不均衡的地區。如果沒有針對性的醫療保健政策來縮小這些地區差異，預計未來幾十年心房顫動的臨床和經濟負擔將進一步增加。

心房顫動 (AF) 仍然是全球最常見的持續性心律不整，由於其與中風、心臟衰竭和死亡風險增加有關，對醫療保健系統構成了重大挑戰。儘管治療方法有所進步，但過去 30 年來，全球 AF 盛行率增加了一倍以上。根據《柳葉刀區域衛生美洲》2025 年 7 月的報告，區域差異繼續影響著整個大陸的 AF 負擔。美國的AF 發生率和盛行率最高，而加拿大的盛行率則經年齡調整後呈下降趨勢。中等收入國家佔 AF 病例的大多數，由於篩檢基礎設施有限，發病率不斷上升。解決這些系統性差異對於減輕 AF 對該地區日益惡化的臨床和經濟影響至關重要。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章全球心房顫動市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 補貼市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全球心房顫動市場分析工具
    • 產業分析-波特五力分析
    • PESTLE分析
  • 技術格局
  • 案例研究分析

4. 2021-2033 年全球心房顫動市場細分分析（依治療類型）

  • 定義和範圍
  • 市佔率分析：治療類型，2024 年和 2033 年
  • 細分儀表板
  • 2021-2033年全球心房顫動治療市場（依治療類型）
  • 藥物治療
    • 2021-2033年藥物治療市場估計與預測
    • 抗心律不整藥物
    • 抗凝血劑
  • 非藥物治療
    • 2021-2033年非藥物治療市場估計與預測
    • 心導管電氣燒灼術
    • 迷宮手術
    • 電去心房顫動

5. 2021-2033 年全球心房顫動市場細分分析（依最終用途）

  • 定義和範圍
  • 2024 年和 2033 年按最終用途分類的市場佔有率分析
  • 細分儀表板
  • 2021-2033年全球心房顫動市場（依最終用途）
  • 醫院
    • 2021-2033年醫院市場估計與預測
  • 專科診所
    • 專科診所市場估計與預測（2021-2033 年）
  • 其他
    • 2021年至2033年其他市場估計與預測

6. 2021-2033 年心房顫動市場細分分析（按地區）

  • 2024 年及 2033 年各地區市佔率分析
  • 市場儀表板：按地區
  • 市場概況：按地區
  • 2024年及2033年各地區心房顫動市佔率
  • 北美洲
    • 北美心房顫動市場，2021-2033
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲心房顫動市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司簡介
    • AtriCure Inc.
    • Boehringer Ingelheim GmbH
    • Boston Scientific Corporation.
    • Bristol-Myers Squibb Corporation
    • Cardio Focus Inc.
    • Sanofi Aventis
    • Biosense Webster Inc.
    • Endoscopic Technologies Inc.
    • Abbott（St. Jude Medical Inc.）
    • Johnsons &Johnson
Product Code: 978-1-68038-004-0

Atrial Fibrillation Market Summary

The global atrial fibrillation market size was estimated at USD 26.89 billion in 2024 and is projected to reach USD 65.33 billion by 2033, growing at a CAGR of 10.44% from 2025 to 2033. The atrial fibrillation market is driven by a growing disease burden, rapid technological evolution in treatment and diagnostics, and the shift toward remote patient monitoring.

Companies capable of integrating these advancements into comprehensive care solutions are likely to lead market growth as clinical practices adapt to more efficient and patient-centric models. Strategic collaborations and acquisitions aimed at expanding access to innovative therapies will further accelerate market competitiveness.

The rising prevalence of atrial fibrillation, driven by aging populations and an increase in risk factors such as hypertension, diabetes, and obesity, is a major factor driving market growth. Atrial fibrillation is one of the leading causes of stroke and heart failure, prompting healthcare systems to prioritize early diagnosis and effective management. The growing patient pool is directly increasing demand for pharmacological treatments and advanced interventional procedures. In May 2024, the CDC highlighted atrial fibrillation (AFib) as the most common heart arrhythmia treated in the U.S. The number of Americans affected by AFib is expected to rise to 12.1 million by 2030. AFib plays a role in roughly 158,000 deaths each year and contributes to about 1 in 7 stroke cases.

Technological advancements in catheter ablation, 3D electro-anatomical mapping, and wearable ECG monitors are enhancing the precision and safety of atrial fibrillation treatments. Integration of artificial intelligence in arrhythmia detection and procedural planning is enabling faster, more accurate diagnosis and targeted therapy. These innovations are expanding treatment options to more patients while improving procedural outcomes and reducing recurrence rates. In April 2025, according to the Heart Rhythm Society (HRS), new research unveiled at Heart Rhythm 2025 showcased how artificial intelligence (AI) is enhancing safety and success rates in atrial fibrillation (AFib) treatments. The AI-driven DeePRISM model enables real-time waveform analysis during ablation procedures, improving outcomes for patients with persistent AFib. Experts highlighted AI's potential to transform electrophysiology by boosting clinical confidence and procedural precision.

The adoption of remote monitoring and telehealth platforms is changing how atrial fibrillation is managed, allowing continuous rhythm monitoring beyond clinical settings. Wearable ECG devices and smartphone-linked applications are providing real-time data to both patients and physicians, supporting proactive management and early intervention. Healthcare providers are leveraging these tools to monitor larger patient populations efficiently, especially for post-procedural follow-up and long-term care. In May 2025, researchers from the Melbourne Brain Centre developed an AI model that can detect silent atrial fibrillation (AF) in stroke patients by analyzing brain MRI scans. The technology showed promising accuracy (AUC 0.81) in differentiating AF-related strokes, offering a non-invasive and efficient detection method. This approach could potentially accelerate diagnosis and personalize stroke care by flagging hidden AF cases needing further cardiac evaluation.

The clustered column chart highlights the incremental rise in atrial fibrillation-related disability-adjusted life years (DALYs) and death rates across the Americas from 1990 to 2021. DALYs increased from 117.14 to 120.68 per 100,000 and death rates rose from 4.18 to 4.84 per 100,000. This reflects a persistent and growing burden on healthcare systems, particularly in regions where access to early detection and advanced treatment remains uneven. Without targeted healthcare policies to bridge these regional disparities, the clinical and economic strain of atrial fibrillation is projected to intensify in the coming decades.

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, posing a substantial challenge to healthcare systems due to its association with stroke, heart failure, and elevated mortality risks. Despite advancements in treatment options, the global prevalence of AF has more than doubled over the past three decades, driven by aging populations and lifestyle-related risk factors. In July 2025, according to The Lancet Regional Health Americas, regional disparities continue to shape the burden of atrial fibrillation across the continent. The U.S. experienced the highest rise in AF incidence and prevalence, while Canada saw a decline after age adjustments. Middle-income countries account for the majority of AF cases, facing rising incidence rates with limited screening infrastructure. Addressing these systemic gaps is critical to mitigating AF's escalating clinical and economic impact in the region.

Global Atrial Fibrillation Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global atrial fibrillation market report based on treatment type, end-use, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmacological Treatment
    • Anti-arrhythmic Drugs
    • Anticoagulant Drugs
  • Non-Pharmacological Treatment
    • Catheter Ablation
    • Radiofrequency
    • HIFU
    • Cryoablation
    • Microwave
    • Laser
    • Maze Surgery
    • Electric Cardioversion
  • End-Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment scope
    • 1.1.2. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. Research Assumptions
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment type outlook
    • 2.2.2. End use outlook
  • 2.3. Competitive Insights

Chapter 3. Global Atrial Fibrillation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Global Atrial Fibrillation: Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTLE Analysis
  • 3.4. Technology Landscape
  • 3.5. Case Study Analysis

Chapter 4. Global Atrial Fibrillation Market Segment Analysis, By Treatment Type, 2021 - 2033 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Treatment Type Market Share Analysis, 2024 & 2033
  • 4.3. Segment Dashboard
  • 4.4. Global Atrial Fibrillation Market, by Treatment Type, 2021 to 2033
  • 4.5. Pharmacological Treatment
    • 4.5.1. Pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.5.2. Anti-arrhythmic Drugs
      • 4.5.2.1. Anti-arrhythmic drugs market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.5.3. Anticoagulant Drugs
      • 4.5.3.1. Anticoagulant drugs market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6. Non-Pharmacological Treatment
    • 4.6.1. Non-pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2. Catheter Ablation
      • 4.6.2.1. Catheter ablation market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.2. Radiofrequency
        • 4.6.2.2.1. Radiofrequency market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.3. HIFU
        • 4.6.2.3.1. HIFU market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.4. Cryoablation
        • 4.6.2.4.1. Cryoablation market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.5. Microwave
        • 4.6.2.5.1. Microwave market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.6. Laser
        • 4.6.2.6.1. Laser market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.3. Maze Surgery
      • 4.6.3.1. Maze surgery market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.4. Electric Cardioversion
      • 4.6.4.1. Electric cardioversion market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Global Atrial Fibrillation Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. End Use Market Share Analysis, 2024 & 2033
  • 5.3. Segment Dashboard
  • 5.4. Global Atrial Fibrillation Market, by End Use, 2021 to 2033
  • 5.5. Hospitals
    • 5.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Specialty Clinics
    • 5.6.1. Specialty Clinics market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Atrial Fibrillation Market Segment Analysis, By Region, 2021 - 2033 (USD Million)

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Regional Market Snapshot
  • 6.4. Atrial Fibrillation Market Share by Region, 2024 & 2033:
  • 6.5. North America
    • 6.5.1. North America atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Scenario
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. U.S. atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Scenario
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Canada atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Scenario
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Mexico atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.2. UK
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Scenario
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. UK atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Scenario
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Germany atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Scenario
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. France atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Scenario
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Italy atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Scenario
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Spain atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Scenario
      • 6.6.7.3. Competitive Scenario
      • 6.6.7.4. Norway atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key Country Dynamics
      • 6.6.8.2. Regulatory Scenario
      • 6.6.8.3. Competitive Scenario
      • 6.6.8.4. Sweden atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key Country Dynamics
      • 6.6.9.2. Regulatory Scenario
      • 6.6.9.3. Competitive Scenario
      • 6.6.9.4. Denmark atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Scenario
      • 6.7.1.3. Competitive Scenario
      • 6.7.1.4. Japan atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Scenario
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. China atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Scenario
      • 6.7.3.3. Competitive Scenario
      • 6.7.3.4. India atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Regulatory Scenario
      • 6.7.4.3. Competitive Scenario
      • 6.7.4.4. Australia atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Regulatory Scenario
      • 6.7.5.3. Competitive Scenario
      • 6.7.5.4. South Korea atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key Country Dynamics
      • 6.7.6.2. Regulatory Scenario
      • 6.7.6.3. Competitive Scenario
      • 6.7.6.4. Thailand atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Scenario
      • 6.8.1.3. Competitive Scenario
      • 6.8.1.4. Brazil atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Scenario
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. Argentina atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key Country Dynamics
      • 6.9.1.2. Regulatory Scenario
      • 6.9.1.3. Competitive Scenario
      • 6.9.1.4. South Africa atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key Country Dynamics
      • 6.9.2.2. Regulatory Scenario
      • 6.9.2.3. Competitive Scenario
      • 6.9.2.4. Saudi Arabia atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key Country Dynamics
      • 6.9.3.2. Regulatory Scenario
      • 6.9.3.3. Competitive Scenario
      • 6.9.3.4. UAE atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key Country Dynamics
      • 6.9.4.2. Regulatory Scenario
      • 6.9.4.3. Competitive Scenario
      • 6.9.4.4. Kuwait atrial fibrillation market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Profiles
    • 7.3.1. AtriCure Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Boehringer Ingelheim GmbH
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Boston Scientific Corporation.
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Bristol- Myers Squibb Corporation
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Cardio Focus Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Sanofi Aventis
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Biosense Webster Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Endoscopic Technologies Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Abbott (St. Jude Medical Inc.)
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Johnsons & Johnson
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Atrial Fibrillation Market, By Treatment Type, 2021 - 2033 (USD Million)
  • Table 4. Global Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 5. Global Atrial Fibrillation Market, By Region, 2021 - 2033 (USD Million)
  • Table 6. North America Atrial Fibrillation Market, By Country, 2021 - 2033 (USD Million)
  • Table 7. North America Atrial Fibrillation Market, By Treatment Type, 2021 - 2033 (USD Million)
  • Table 8. North America Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 9. U.S. Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 10. U.S. Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11. Canada Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 12. Canada Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13. Mexico Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 14. Mexico Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 15. Europe Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 16. Europe Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 17. Europe Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 18. UK. Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 19. UK. Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20. Germany Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 21. Germany Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 22. France Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 23. France Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24. Italy Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 25. Italy Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 26. Spain Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 27. Spain Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 28. Denmark Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 29. Denmark Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30. Sweden Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 31. Sweden Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 32. Norway Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 33. Norway Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 37. Japan Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 38. Japan Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39. China Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 40. China Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 41. India Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 42. India Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 43. Australia Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 44. Australia Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45. Thailand Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 46. Thailand Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 47. South Korea Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 48. South Korea Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 49. Latin America Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 50. Latin America Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 51. Latin America Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52. Brazil Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 53. Brazil Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54. Argentina Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 55. Argentina Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 59. South Africa Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 60. South Africa Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 63. UAE Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 64. UAE Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 65. Kuwait Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 66. Kuwait Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Global atrial fibrillation market: outlook
  • Fig. 9 Global atrial fibrillation competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Ancillary market outlook
  • Fig. 12 Global atrial fibrillation market driver impact
  • Fig. 13 Global atrial fibrillation market restraint impact
  • Fig. 14 Porter's Analysis
  • Fig. 15 PESTLE Analysis
  • Fig. 16 Global atrial fibrillation market: Treatment type movement analysis
  • Fig. 17 Global atrial fibrillation market: Treatment type outlook and key takeaways
  • Fig. 18 Pharmacological treatment market estimates and forecast, 2021 - 2033
  • Fig. 19 Anti-arrythmic drugs market estimates and forecast, 2021 - 2033
  • Fig. 20 Anticoagulant drugs market estimates and forecast, 2021 - 2033
  • Fig. 21 Non-pharmacological treatment market estimates and forecast, 2021 - 2033
  • Fig. 22 Catheter ablation market estimates and forecast, 2021 - 2033
  • Fig. 23 Radiofrequency market estimates and forecast, 2021 - 2033
  • Fig. 24 HIFU market estimates and forecast, 2021 - 2033
  • Fig. 25 Cryoablation market estimates and forecast, 2021 - 2033
  • Fig. 26 Microwave market estimates and forecast, 2021 - 2033
  • Fig. 27 Laser market estimates and forecast, 2021 - 2033
  • Fig. 28 Maze surgery market estimates and forecast, 2021 - 2033
  • Fig. 29 Electric cardioversion market estimates and forecast, 2021 - 2033
  • Fig. 30 Global atrial fibrillation market: End use movement analysis
  • Fig. 31 Global atrial fibrillation market: End use outlook and key takeaways
  • Fig. 32 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 33 Specialty clinics market estimates and forecasts,2021 - 2033
  • Fig. 34 Others market estimates and forecasts,2021 - 2033
  • Fig. 35 Global atrial fibrillation market: Regional movement analysis
  • Fig. 36 Global atrial fibrillation market: Regional outlook and key takeaways
  • Fig. 37 North America atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 U.S. atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Canada atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Mexico atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Europe atrial fibrillation market estimates and forecasts, 2021 - 2033, (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 UK atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Germany atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Spain atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Norway atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Asia Pacific atrial fibrillation market estimates and forecasts, 2021 - 2033, (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Japan atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 China atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 India atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Australia atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Korea atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Thailand atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America atrial fibrillation market estimates and forecasts, 2021 - 2033, (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Brazil atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Argentina atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 MEA atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Kuwait atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key company categorization
  • Fig. 89 Heat map analysis 2024